PMID- 15363475 OWN - NLM STAT- MEDLINE DCOM- 20050111 LR - 20200109 IS - 0924-9338 (Print) IS - 0924-9338 (Linking) VI - 19 IP - 6 DP - 2004 Sep TI - Safety and tolerability of olanzapine compared with other antipsychotics in the treatment of elderly patients with schizophrenia: a naturalistic study. PG - 358-65 AB - OBJECTIVE: To evaluate the safety and tolerability of olanzapine in the treatment of elderly patients with schizophrenia. METHODS: A total of 135 outpatients with schizophrenia > or =60 years of age were treated with olanzapine (n = 105) or another antipsychotic (n = 30) and followed up for 6 months. Safety measures included the recording of spontaneous adverse events and extrapyramidal symptoms (EPS). Clinical status and effectiveness of the medications were measured using the Clinical Global Impressions-Severity of Illness and the Global Assessment of Function (GAF) scales. Quality of life was assessed by means of the Spanish version of the EuroQol. The Awad scale was applied to evaluate patients' subjective attitude towards medication. RESULTS: The incidence of overall adverse events and EPS was non-significantly lower in patients treated with olanzapine than in patients treated with other antipsychotics. The use of anticholinergic drugs was significantly lower (P = 0.04) in patients treated with olanzapine. Both groups of patients experienced similar improvements in Clinical Global Impressions-Severity and GAF scores. Non-significantly greater improvement in the acceptance of medication occurred at endpoint in olanzapine-treated patients than in control patients as measured by the Awad scale. The improvement in the EuroQol quality of life scale achieved at the end of study did not differ between both treatment groups. CONCLUSIONS: Results from this naturalistic study showed that olanzapine was as safe and effective as other antipsychotic drugs in the treatment of elderly patients with schizophrenia. FAU - Ciudad, Antonio AU - Ciudad A AD - Lilly Research Laboratories, 30 Avenida de la Industria, Alcobendas CP28108, Madrid, Spain. ciudad_antonio@lilly.com FAU - Montes, Jose-Manuel AU - Montes JM FAU - Olivares, Jose-Manuel AU - Olivares JM FAU - Gomez, Juan-Carlos AU - Gomez JC CN - EFESO Study Group LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Eur Psychiatry JT - European psychiatry : the journal of the Association of European Psychiatrists JID - 9111820 RN - 0 (Antipsychotic Agents) RN - 12794-10-4 (Benzodiazepines) RN - L6UH7ZF8HC (Risperidone) RN - N7U69T4SZR (Olanzapine) SB - IM MH - Aged MH - Antipsychotic Agents/adverse effects/*therapeutic use MH - Attitude to Health MH - Basal Ganglia Diseases/chemically induced/epidemiology MH - Benzodiazepines/adverse effects/*therapeutic use MH - *Drug Tolerance MH - Drug Utilization/*statistics & numerical data MH - Female MH - Humans MH - Male MH - Middle Aged MH - Olanzapine MH - Prospective Studies MH - Quality of Life MH - Risperidone/adverse effects/*therapeutic use MH - Schizophrenia/classification/diagnosis/*drug therapy MH - Severity of Illness Index MH - Surveys and Questionnaires EDAT- 2004/09/15 05:00 MHDA- 2005/01/12 09:00 CRDT- 2004/09/15 05:00 PHST- 2003/09/15 00:00 [received] PHST- 2004/04/20 00:00 [revised] PHST- 2004/04/26 00:00 [accepted] PHST- 2004/09/15 05:00 [pubmed] PHST- 2005/01/12 09:00 [medline] PHST- 2004/09/15 05:00 [entrez] AID - S0924933804001397 [pii] AID - 10.1016/j.eurpsy.2004.06.008 [doi] PST - ppublish SO - Eur Psychiatry. 2004 Sep;19(6):358-65. doi: 10.1016/j.eurpsy.2004.06.008.